NewKerala.com

Key Points

Scientists have developed a groundbreaking mRNA vaccine approach that could revolutionize immunization strategies for rapidly mutating viruses. The new method dramatically reduces vaccine production costs by using 40 times less mRNA compared to current technologies. By creating a "consensus spike protein" design, researchers demonstrated potential for broader protection against multiple viral strains. This innovative platform could transform vaccine development for diseases like COVID-19 and potentially bird flu.

Key Points: Breakthrough mRNA Vaccine Design Cuts Costs Fights Viral Variants

  • New mRNA vaccine platform requires 40x less dose than conventional vaccines
  • Consensus spike protein design enables broader viral strain protection
  • Researchers successfully tested approach in mice models
  • Potential application for multiple evolving RNA viruses
2 min read

New mRNA vaccine is more effective, less costly to develop: Study

Pittsburgh researchers develop innovative mRNA vaccine platform offering broader protection and lower production costs for evolving viruses like COVID-19

"This has the potential for more lasting immunity that would not require updating - Dr. Suresh Kuchipudi"

Washington, DC, June 8

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at the University of Pittsburgh School of Public Health and the Pennsylvania State University.

The study was published today in npj Vaccines.

Though highly effective at inducing an immune response, current mRNA vaccines, such as those used to prevent COVID-19, present two significant challenges: the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen.

"The virus changes, moving the goal post, and updating the vaccine takes some time," said senior author Suresh Kuchipudi, Ph.D., chair of Infectious Diseases and Microbiology at Pitt Public Health.

To address these challenges, the researchers created a proof-of-concept COVID-19 vaccine using what's known as a"trans-amplifying" mRNA platform.

In this approach, the mRNA is separated into two fragments -- the antigen sequence and the replicase sequence -- the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale.

Additionally, the researchers analysed the spike-protein sequences of all known variants of SARS-CoV-2 for commonalities, rendering what's known as a "consensus spike protein" as the basis for the vaccine's antigen.

In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2.

"This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection," said Kuchipudi.

"Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine."

The lessons learned from this study could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential, Kuchipudi said.

"We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu," added Kuchipudi.

- ANI

Share this article:

Reader Comments

P
Priya K.
This is such promising research! 🇮🇳 If this technology can make vaccines more affordable and effective, it could be a game-changer for India's public health system. Our population is so large that cost-effective solutions are desperately needed. Hope Indian researchers can collaborate on similar innovations.
R
Rahul S.
While this sounds great, I wonder how long it will take to reach developing countries. During COVID, we saw how vaccine inequality played out. Hope this time the technology transfer happens faster so Indian pharma companies can manufacture it locally.
A
Ananya M.
The 40 times less mRNA requirement is impressive! This could mean more doses from same facilities. But I hope they test it thoroughly - we've seen how new vaccine tech sometimes has unexpected side effects. Safety first, always.
V
Vikram J.
Good to see science progressing, but let's not forget traditional medicine systems like Ayurveda that have helped us through pandemics for centuries. Modern and traditional approaches should work together for holistic healthcare.
S
Sunita P.
As someone who lost family members to COVID, I welcome any advancement that can prevent such tragedies. The "consensus spike protein" approach sounds clever - like finding the common thread in all variants. Hope this gets fast-tracked for approval!
A
Arjun N.
The bird flu application mentioned is interesting. With India being a major poultry producer, this could protect both our food security and farmers' livelihoods. Government should monitor this research closely and invest in similar domestic capabilities.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50